NHS Dudley Health Economy Medicines Formulary
Home > 10 Musculoskeletal and joint diseases > 10.1 Drugs used in rheumatic diseases and gout > 10.1.4 Gout and cytotoxic-induced hyperuricaemia > Hyperuricaemia - febuxostat - NICE TAG TA164

Hyperuricaemia - febuxostat - NICE TAG TA164

1.1 Febuxostat, within its marketing authorisation, is recommended as an option for the management of chronic hyperuricaemia in gout only for people who are intolerant of allopurinol (as defined in section 1.2) or for whom allopurinol is contraindicated.

1.2 For the purposes of this guidance, intolerance of allopurinol is defined as adverse effects that are sufficiently severe to warrant its discontinuation, or to prevent full dose escalation for optimal effectiveness as appropriate within its marketing authorisation.

1.3 People currently receiving febuxostat should have the option to continue therapy until they and their clinicians consider it appropriate to stop

 

https://www.nice.org.uk/guidance/TA164

Site by Devopa
© Copyright 2020 NHS. All rights reserved.